Showing 5831-5840 of 23187 results for "".
"You don't have to know programming to create solutions," says Dr. Michal Nedoszytko, Creator of PostVisit.ai
https://reachmd.com/programs/the-convergence/Michal-Nedoszytko-PostVisit-ai/54781/The next wave of AI innovation is here, and clinicians are at the forefront. Dr. Brian McDonough sits down with Dr. Michal Nedoszytko, an interventional and general cardiologist and the creator of PreVisit.ai and PostVisit.ai, to learn how he's turning everyday clinical challenges into AI-driven sInflammatory Bowel Disease Emergencies: Toward Faster Identification & Management
https://reachmd.com/programs/crohns-colitis-foundation-perspectives/inflammatory-bowel-disease-emergencies-toward-faster-identification-management/8504/Dr. Kim Isaacs reviews the most severe complications from Crohn's disease and ulcerative colitis, and how to best identify and manage them quickly.Sorry Works!
https://reachmd.com/programs/clinicians-roundtable/sorry-works/1731/Join James Saxton from Stevens & Lee law firm and Doug Wojcieszak, Founder of the Sorry Works! Coalition discuss their new book, Sorry Works! Disclosure, Apology and Relationships Prevent Medical Malpractice Claims.Advances in Parenteral Nutrition: Examining Multi-Source Lipid Emulsions
https://reachmd.com/programs/gi-insights/advances-parenteral-nutrition-multi-source-lipid-emulsions/37244/Evolving evidence supports the shift from single-source to multi-source intravenous lipid emulsions in parenteral nutrition. These newer formulations may offer improved metabolic, inflammatory, and hepatic outcomes, particularly for vulnerable patient populations. Joining Dr. Charles Turck to discusImmune Checkpoint Inhibitors Show Promise in Patients with Oncogene Driver-Negative NSCLC Who Have Never Smoked
https://reachmd.com/programs/project-oncology/immune-checkpoint-inhibitors-show-promise-in-patients-with-oncogene-driver-negative-nsclc-who-have-never-smoked/33000/A multi-institutional study presented at ASCO 2025 offers critical new insights into a long-overlooked subset of non-small cell lung cancer (NSCLC) patients: never-smokers without actionable oncogenic drivers. Read about the study’s findings on the key predictors of response to immune checkpoint inhBattling Burnout: Advice for Healthcare Professionals
https://reachmd.com/programs/clinicians-roundtable/battling-burnout-advice-for-healthcare-professionals/12136/What are some strategies we can implement to help prevent burnout while practicing medicine?Planting Seeds: Prostate Cancer Treatment
https://reachmd.com/programs/clinicians-roundtable/planting-seeds-prostate-cancer-treatment/2282/Dr. Michael Greenberg speaks with Dr. Brian Moran, Medical Director of the Chicago Prostate Cancer Treatment Center, about the various treatments available for treating prostate cancer with an emphasis on brachytherapy.Psoriasis Update for Clinicians
https://reachmd.com/programs/clinicians-roundtable/psoriasis-update-for-clinicians/1272/Dr. Michael Greenberg welcomes Dr. Mark Lebwohl, Chairman and Professor of Dermatology at Mt. Sinai Medical Center, NY, who discusses current treatments in psoriasis.Epigenetics in the Environment: An Exploration of Genetics & Chronic Health Conditions
https://reachmd.com/programs/clinicians-roundtable/epigenetics-in-the-environment-an-exploration-of-genetics-chronic-health-conditions/12630/What does the inclusion of epigenetics in medicine mean for patients with chronic health conditions?Everest ER: Practicing Medicine at 17,000 Feet
https://reachmd.com/programs/clinicians-roundtable/everest-er-practicing-medicine-17000-feet/9692/Dr. Luanne Freer talks about the perils and triumphs of founding and operating a clinic at 17,000 feet.